Managing Pediatric Patients with Psoriasis

  • Susan Bard
  • Daniele Torchia
  • Lawrence A. Schachner
Review Article

DOI: 10.2165/1153415-S0-000000000-00000

Cite this article as:
Bard, S., Torchia, D. & Schachner, L.A. AM J Clin Dermatol (2010) 11(Suppl 1): 15. doi:10.2165/1153415-S0-000000000-00000
  • 103 Downloads

Abstract

Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. InEurope, etanercept has recently been approved for children aged 8 years and over. Data froma well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept iswell tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Susan Bard
    • 1
  • Daniele Torchia
    • 1
  • Lawrence A. Schachner
    • 1
  1. 1.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations